Therefore, the adoption of NACT for T2N1M0 stage HR + /HER2- breast cancer patients warrants careful consideration, particularly for those with low tumor grade, who are more inclined to be non-pCR after undergoing NACT. This evidence concerns the gene ERBB2 and neoplasm.